Jul. 18 at 12:06 PM
$SLBT Complete Tumor Elimination: Direct administration of γδ T cells achieved complete eradication of the tumor by day 26 post-treatment at the highest dose tested (an 8:1 ratio of immune cells to cancer cells).
Dose-Dependent Success: The research demonstrated the feasibility and effectiveness of repeated direct-to-brain dosing, showing that the tumor-suppressing benefits scaled positively with the dosage.
Clean Safety Profile: Comprehensive health screens and blood panels confirmed that the treatment was well-tolerated in the study, showing no major safety concerns or adverse health effects.
This is absolutely mind-boggling news released at this show - this will definitely get the attention of some major institutions and pharmaceuticals.
Still early in trials but to to be effective with an incredible safety profile is $$. Will definitely get their drug orphan designation soon and onto next trials.
